Navigation Links
Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
Date:5/28/2008

0 YEARS OLD: RESULTS

OF A PHASE 1 STUDY

Abstract #0515

Poster session 2: Acute myeloid leukemia -- Clinical II

Saturday, June 14, 2008, 6:00 p.m. - 7:15 p.m. CEST

o A PHASE 1 TRIAL OF SNS-032, A POTENT AND SPECIFIC CDK 2, 7 AND 9

INHIBITOR, IN CHRONIC LYMPHOCYTIC LEUKEMIA AND MULTIPLE MYELOMA

Abstract #0792

Poster session 2: Novel therapies, drug resistance and pharmacology II

Saturday, June 14, 2008, 6:00 p.m. - 7:15 p.m. CEST

All clinical data presented will be available following each conference on the Sunesis corporate website at http://www.sunesis.com.

About Sunesis' Oncology Programs

Sunesis has built a rich portfolio of product candidates in oncology focused on novel pathways and targets, including inhibition of the cell-cycle and survival signaling.

Sunesis' lead compound, voreloxin (formerly SNS-595), is a novel naphthyridine analog, structurally related to quinolones, a class of compounds which has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, irreversible G2 arrest and rapid apoptosis. Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients, in a Phase 1b clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML, and as a single agent in a Phase 2 clinical trial in platinum-resistant ovarian cancer. In clinical trials conducted to date, voreloxin has been generally well tolerated and has shown objective responses in both solid and hematologic tumor types.

SNS-032, Sunesis' potent and selective inhibitor of cyclin-dependent kinases 2, 7 and 9, is being evaluated in a Phase 1 clinical trial in chronic lymphocytic leuke
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
4. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
5. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... HARRISBURG, Pa. , Sept. 23, 2014 ... prescription drugs Sat., Sept. 27, as part of National ... anonymous, no questions asked. Take-Back Day is ... Drug Enforcement Administration (DEA), aimed at encouraging the public ... that are prone to abuse and theft. ...
(Date:9/23/2014)... 2014 Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a ... diseases and cholesterol gallstones, announced today that the ... approved its request for Fast Track Designation of ... Non-Alcoholic Steato-Hepatitis, or NASH.  FDA ...
(Date:9/23/2014)... , Sept 23, 2014  Vesselon, Inc. today announced ... of Directors, effective September 15, 2014. Dr. Raths, appointment ... its placement agent to market a private preferred Series ... early stroke treatment. "Jurgen,s deep experience across ... a great asset to Vesselon as we develop our ...
Breaking Medicine Technology:Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 2Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 3Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 3
... Novavax, Inc. (Nasdaq:,NVAX) today announced that it ... vaccine candidate against Severe Acute Respiratory Syndrome,(SARS). The ... Institutes of Health (NIH) to continue preclinical development ... "Until now, it has been difficult to ...
... Three of Four HUMIRA Patients from CHARM Study in Remission ... ... May 21 Results from an,open-label extension study of two ... patients treated with,HUMIRA(R) (adalimumab) achieved long-term clinical remission and clinical,response, ...
Cached Medicine Technology:Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development 2Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development 3Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 2Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 3Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 4Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 5Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 6Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 7
(Date:9/23/2014)... CA (PRWEB) September 23, 2014 Oaksterdam ... Industry Today . In its first post, the University ... growing and changing cannabis industry. , The cannabis industry ... Colorado alone is expecting an 18-month boost of more ... and adult use pot sales. And, the new legal ...
(Date:9/23/2014)... throughout the first year follow a set of ... syllables and first words. However, previous research had ... differ between hearing and deaf infants. Now, University ... primarily motivated by infants, ability to hear their ... who received cochlear implants to help correct their ...
(Date:9/23/2014)... FL (PRWEB) September 23, 2014 ... of the newly renovated Women’s Health Center on ... feet of space, the specially designed center offers ... in East Pasco County. The Women’s Health Center ... pelvic floor health, labor and delivery through The ...
(Date:9/23/2014)... "The primary purpose of the CALL LIGHT CADDY is ... Ca.. "Call lights are often found on the floor, lost ... pole out of the patient's reach. In order to make ... need it, I created this caddy." , She developed the ... within easy reach. The accessory ensures that the call device ...
(Date:9/23/2014)... studies found that FDG-PET technology is less accurate ... regions where infections like histoplasmosis or tuberculosis are ... cancer could lead to unnecessary tests and surgeries ... , Histoplasmosis and other fungal diseases are ... bird droppings and are found in soils. , ...
Breaking Medicine News(10 mins):Health News:Oaksterdam University Addresses "Why Quality Training Matters in a Growing Marijuana Industry" in First Blog Post 2Health News:Oaksterdam University Addresses "Why Quality Training Matters in a Growing Marijuana Industry" in First Blog Post 3Health News:Infant cooing, babbling linked to hearing ability, MU researcher finds 2Health News:Florida Hospital Zephyrhills Celebrates Grand Opening of Women’s Health Center 2Health News:Florida Hospital Zephyrhills Celebrates Grand Opening of Women’s Health Center 3Health News:Study questions accuracy of lung cancer screens in some geographic regions 2
... the time in emergency rooms , , TUESDAY, Dec. 18 (HealthDay ... someone is having a heart attack, they are mistaken 9.2 ... that minutes matter with these patients and doctors have to ... say researchers from the Minneapolis Heart Institute Foundation. , "Our ...
... three and older in the United States would carry ... the 2008 University of Louisville Grawemeyer Award in Education. ... nations young children, fill a gap for working families, ... boost the economy, award winners Edward Zigler, Walter Gilliam ...
... led by Mayo Clinic have designed a technique that uses ... cells that spread from primary tumors to other parts of ... shows that this technology could be the basis for a ... appeared in the Dec. 9 online issue of Nature Medicine. ...
... inexpensive infection control measures, hospitals around the world could prevent ... TB), according to a new study in The Lancet by ... Wings for its ability to spread and kill rapidly, XDR ... identified in all regions of the world, including the United ...
... for patients with spinal cord injuries can stimulate ... compensatory changes in the brain, say Canadian researchers. ... function and the ability to walk. , A ... the remarkable benefits of rehabilitation training after a ...
... remains America,s No. 1 killer, AHA says , , TUESDAY, ... death rates in the United States are declining, the ... the nation, according to the American Heart Association. , ... for many people, according to the American Heart Association,s ...
Cached Medicine News:Health News:Diagnosis of Heart Attack Can Be Wrong 2Health News:Researchers train the immune system to deliver virus that destroys cancer in lab models 2Health News:Researchers train the immune system to deliver virus that destroys cancer in lab models 3Health News:Simple strategy could prevent half of deadly tuberculosis infections 2Health News:Intensive training post-spinal cord injury can stimulate repair in brain and spinal cord 2Health News:U.S. Heart Disease Death Rates Falling 2Health News:U.S. Heart Disease Death Rates Falling 3
... cage system provides anterior column support for ... from T1 to L5. The system consists ... polymer cages that are stacked to a ... Peek Carbon fiber reinforced polymer material emulates ...
... is an extrudable, moldable bone void filler that ... anywhere in the skeletal system, including extremities, the ... as a temporary scaffolding for new bone formation. ... X-ray, making healing easier to assess. Boneplast kit ...
... CE mark for its synthetic bone substitute Ossatura. ... of a smart material, i.e. a material that ... of events in the musculo-skeletal system that results ... and improved fusion, and reduces in part or ...
... Cerasorb bone regeneration ... beta-tricalcium phosphate composite ensures ... unique spherical structure maximizes ... Permeability is the most ...
Medicine Products: